Clinical Investigator, Hale Family Center For Pancreatic Cancer Research
Department Of Medical Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Bio Research Interests Key Publications
Bio
Dr. Cleary is a medical oncologist at the Dana-Farber Cancer Institute who specializes in treating gastrointestinal cancers. After graduating from Rutgers College and Albert Einstein Medical School, he completed an internal medicine residency at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. His research interest focuses on the identification and development of novel therapeutic approaches for gastrointestinal malignancies. He collaborates on translational research projects with basic science laboratories and is the principal investigator on clinical trials evaluating targeted and immune-directed therapies. He serves as the Co-Director of Clinical Trials in the Center for Gastrointestinal Oncology at Dana-Farber. He has won awards for patient care at Dana-Farber and teaching at Harvard Medical School.
Research Interests
As the Associate Director Of Clinical Research in the Gastrointestinal Cancer Center at Dana-Farber and clinical liaison for gastrointestinal malignancies for both the Dana-Farber Early Drug Development Center (EDDC) and the Dana-Farber Center For Immunotherapy, Dr. Cleary has developed extensive experience leading clinical trials. A major focus of his research is in developing therapies that exploit double-strand DNA damage repair (DDR) deficiency in metastatic pancreatic adenocarcinoma. He is currently is leading a phase 2 clinical trial of the PARP inhibitor Niraparib in pancreatic cancer patients with DNA repair deficiencies. Along with Dr. Alan D’Andrea, he is the co-leader of a Stand Up To Cancer (SU2C)/ Lustgarten Foundation grant for evaluating DNA repair inhibitors in pancreatic cancer organoids and patient-derived xenograft (PDX) models. The goal of this grant is to utilize these preclinical studies to identify the most potent combinatorial strategies, along with predictive biomarkers, to inform the design of clinical trials for pancreatic cancer patients.
Key Publications
Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA, Beg MS, Murphy JE, Mavroukakis S, Zaki A, Schlechter BL, Sanoff H, Manz C, Wolpin BM, Arlen P, Lacy J, Cleary JM. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249720. doi:10.1001/jamanetworkopen.2022.49720.PMID: 36602796
Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, Singh H1, Wen PY, Bardeesy N, Zoete V, Wolpin BM, Losman JA. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. NPG Precis Oncol. 2022, Sep 2;6(1):61. PMID: 36056177; PMCID: PMC9440204; doi: 10.1038/s41698-022-00304-5.
Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers (Basel). 2022 Dec 16;14(24):6223. doi: 10.3390/cancers14246223.
Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta H, Rubinson D, Fetter IF, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais L, Loftus M, Shinagare AB, Abrams T, Clancy T, Wang J, Patel A, Brichory F, Chessex A, Sullivan R, Keller RB, Denning S, Hill E, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AC, Corcoran R, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021;11(10):2488-05. PMID: 33926920
Cleary JM, Wolpin BM, Dougan SK, Raghavan S, Singh H, Huffman B, Sethi NS, Nowak JA, Shapiro GI, Aguirre AJ, D’Andrea AD. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Can Res. 2021 Jul 20. DOI: 10.1158/1078-0432.CCR-21-1367 [Online ahead of print] PMID: 34285063
